A Comprehensive Prospective Study to Understand Chikungunya Infection in Delhi Region during 2010-2011

Singh Pradeep Kumar*, Dar Lalit, Broor Shobha

Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India

*Corresponding author: psingh1976a@gmail.com

Received September 23, 2020; Revised October 25, 2020; Accepted November 02, 2020

Abstract

INTRODUCTION: Chikungunya is an arbovirus causing febrile illness with high strike rate and is known for outbreaks in more than 60 countries globally. During 2010-2011 unusual high number of suspected Chikungunya infection patients attended AIIMS OPD, Delhi, India. The NCR region with its semiarid geography restricts arbovirus outbreaks to monsoon months and is previously known for Dengue outbreaks although Chikungunya outbreaks were previously unknown to the region. The surge in suspected Chikungunya infection cases indicates a possible outbreak in the NCR region. This comprehensive prospective and follow-up study was designed to understand the Chikungunya infection among patients attending AIIMS OPD during 2010-11.

METHOD: During June 2010 to Dec 2011, 2346 blood samples were collected from outpatients and inpatients attending AIIMS OPD, New Delhi. Samples were grouped in acute and chronic cases. Some patients were also enrolled for year-long follow-up study. Serum samples were tested for CHIKV using PCR and for IgM antibodies to chikungunya virus by IgM-capture ELISA. Real-time PCR was performed targeting the E1 gene for viral load determination in patient sera. RESULT: CHIKV positivity of 35% (746/2112) in acute and 67% (156/234) in chronic suspected cases were found by ELISA. most affected patients belonged to the age group >30-45 yrs. and above in both genders. Acute confirmed cases included 383 (51.3%) females and 363 (48.7%) males and chronic includes 92 (58.9%) females and 64 (41.1%) males. Clinical symptoms include polyarthralgia, fever, and rashes. Maximum positivity was seen in Oct-Nov of both years. During follow-up study, 118 patients enrolled, persisting polyarthralgia and anti-CHIKV IgM was detected up to 2 years while circulating CHIKV was detected by PCR up to 3 months in few patients. CONCLUSION: Chikungunya virus has emerged in Delhi during 2010 and contributed to about 30-40% of fever and arthralgia. CHIKV prevalence is highest in post monsoon month of October. The virus can remain in blood circulation for weeks, while anti-CHIKV IgM can persist for more than a year with complaints of periodic polyarthralgia.

Keywords: Chikungunya, India, polyarthralgia, followup

Cite This Article: Singh Pradeep Kumar, and Dar Lalit, Broor Shobha, “A Comprehensive Prospective Study to Understand Chikungunya Infection in Delhi Region during 2010-2011.” American Journal of Microbiological Research, vol. 8, no. 4 (2020): 117-135. doi: 10.12691/ajmr-8-4-2.

1. Introduction

1.1. Background

In 1955 first published report of Chikungunya fever was reported from Makonde Plateau in the Southern Province of Tanganika of Africa by Robinson MC [1]. Due to its clinical features a local name was rapidly used by natives to define the disease i.e. Chikungunya meaning “that which bends up”. In 1956 R. W. Ross isolated the Chikungunya Virus (CHIKV) from serum samples obtained from acute phase Chikungunya patients from Newala district of Tanganyika. CHIKV has RNA genome consisting of a linear, positive sense; single-stranded RNA molecule of approximately 11.8 kilobases [2,3]. In Africa CHIKV is maintained in a Sylvatic cycle among Aedes species mosquitoes, wild primates, squirrels, birds and rodents [4]. In Asia including India the disease is transmitted by A. aegypti and A. albopictus [5,6].

Since 1953 then many other epidemics of CHIKV have been reported from different countries of Africa, Asia, America and Europe. Many countries also reported re-emergence of CHIKV with large proportion of population affected [7,8]. First Chikungunya outbreak in Asia was reported from the Philippines in 1954, with reemergence in 1956 and 1968. During the 1970s, frequent outbreaks occurred in southern and south-east Asia but subsequently decreased in incidence, and virus activity seemed to have ceased in many areas, with small localized outbreaks only. Similar outbreaks and sporadic cases have been confirmed in Thailand, Sri Lanka, Vietnam, Pakistan, Cambodia, Laos, Burma, Philippines and India. Between 1982 and
1985, the virus spread into Indonesia and was identified in south Sumatra, Java, and other nearby Islands. In 1998 the first outbreak in Malaysia was recorded [7,8,9,10,11,12].

The second documented CHIKV emergence began in coastal Kenya in 2004 [13] that spreads via air or sea route to Islands in the Indian oceans including La Reunion and other nearby countries including India. Chikungunya spreading via infected air traveler was later documented from USA, Germany and France [14,15,16]. During period of March 2005 to December 2006 Reunion Island witness the largest outbreak of CHIKV with more than 266,000 people infected (36% of total population). This outbreak was later linked to case reports in other countries of Europe, America and Asia [17,18].

After 2005, till 2018 Chikungunya infection was reported from various countries of Asia, Africa, Europe, America and Australia [19-43].

The classic clinical symptoms after infection by CHIKV are abrupt febrile illness (temperature usually >38.9°C), polyarthralgia and maculopapular rash (a form of microvasculitis, more than 1/3rd of cases). Typically, CHIKV causes in human an abrupt onset of fever (85-100%), incapacitating arthralgia (87-99%) [44], myalgia (60-93%) and sometimes a rash (35%). Rashes involve extremities and trunk of patient [45]. Other symptoms, such as headache, asthenia, nausea, vomiting etc. have also been described. Fevers lasts from 1-8 days while rashes typically resolved in 3-5 days [46,47,48,49,50,51]. The acute signs and symptoms usually resolve in less than 2 weeks, but arthralgia may linger for weeks, months or even years and this is a clinical sign that may distinguish CHIKV from DV infection.

Unusual complications such as hepatitis, pneumonia, mild hemorrhage, pre-renal failure, cardiologic manifestations (heart failure, myocarditis) and neurologic diseases are also seen in Chikungunya patients. Of critical note, these severe cases were reported from hospitalized cohorts of patients and may be related to several underlying medical conditions; most commonly with hypertension, respiratory conditions and diabetes mellitus [17,49,52,53].

Moreover, while CHIKV-associated fatalities had not been reported prior to this outbreak, at least 260 persons infected with CHIKV died in La Réunion Island [54]. Finally, although never described before, cases of severe neonatal CHIKV infection were observed in La Réunion Island, associated with severe disease and encephalopathy, and suggested a possible mother-to-child CHIKV transmission, which has since been confirmed [55].

Chikungunya was first reported in 1963 from Kolkata (Previously Calcutta) [12], following that there are several reports of Chikungunya virus infection from different parts of India, mainly southern states [56,57,58,59]. In 1973 the last outbreak of Chikungunya was reported from Barsi Maharashtra India and after that it was thought that Chikungunya has disappeared from India. In 2005 when large outbreaks of Chikungunya were reported from countries in Indian Ocean like Réunion Island, Maldives Mauritius etc., at almost the same time by end of 2005 outbreaks of Chikungunya started in India in coastal Andhra Pradesh and Karnataka. From February 2006, to Oct 10, 2006, the WHO regional office for south-east Asia and the National Vector Borne Disease Control Programme of India reported that 151 districts located in ten states/provinces of India had been hit by Chikungunya fever. About 1·36 million suspected cases had been reported in south India, where 539 million people live. In some states attack rates as high as 45% were reported. Andhra Pradesh was the first Indian state to report suspected cases in December 2005, and was also one of the worst affected states (more than 80 000 suspected cases) [60]. Subsequently, movement of Chikungunya was seen to Central Western Indian states (Gujarat, Madhya Pradesh and Rajasthan) [47,61]. By the end of 2006, Chikungunya reaches northern parts of India evidenced by reported sporadic cases of CHIKV infection along with massive dengue outbreak in Delhi [62,63], although only few cases were also reported from Haryana and Uttar Pradesh (NVBDCP). After 2007 nearly all states of India were reported with Chikungunya infection [64].

From 2006 to 2009 total of 1,666,412 (~1.6 million cases of Chikungunya from nearly all states of India were reported by NVBDCP, India, of which only 795 cases were reported from Delhi [64]. Delhi and NCR have been reporting occasional Chikungunya cases but no prospective study has been carried out to estimate the prevalence of Chikungunya infection in suspected cases.

Present study was designed as comprehensive prospective study to understand Chikungunya infection in Delhi region during 2010-2011 that provides a detailed account of seasonality and magnitude of Chikungunya infection in this region.

2. Methods and Materials

2.1. Study

Laboratory investigation for diagnosis of Chikungunya infection in suspected patients.

2.1.1. Patients Enrolled in the Study

Blood samples were collected from outpatients and inpatients suspected of Chikungunya infection attending at All India Institute of Medical Sciences New Delhi during one and half year from Mid June 2010 to Dec 2011. The detailed clinical history including duration of illness and sample was obtained from all patients in prescribed Performa after obtaining their consent. (Figure 1)

Criteria for diagnosis (adapted from WHO guidelines):

1. Clinical criteria: acute onset of fever >38.5°C and severe arthralgia/arthritis not explained by other medical conditions

2. Epidemiological criteria: residing or having visited epidemic areas, having reported transmission within 15 days prior to the onset of symptoms

3. Laboratory criteria: at least one of the following tests in the acute phase: - Virus isolation - Presence of viral RNA by RT-PCR - Presence of virus specific IgM antibodies in single serum sample collected in acute or convalescent stage. - Four-fold rising of IgG titers in samples collected at least three weeks apart.

2. Case definition for surveillance:

Possible case: a patient meeting clinical criteria;

Probable case: a patient meeting both the clinical and epidemiological criteria;

Confirmed case: a patient meeting the laboratory criteria, irrespective of the clinical presentation.
2.1.2. Inclusion and Exclusion Criteria

All patients presented with fever were including, acute illness was defined within <15 days of onset of illness with presence of fever, and/or polyarthralgia, and/or rash. Chronic/persisting illness was defined as patients with persisting polyarthralgia and past history of fever. Patients who refuse to give consent were excluded from the study.

2.1.3. Controls

Forty (40) unrelated healthy controls (20 male and 20 female) of different age group with no previous history of polyarthralgia were enrolled in the control group. Consent was also obtained from the control group.

2.1.4. Follow-up of Confirmed Cases of Chikungunya Infection

To understand the CHIKV infection progression, 75 patients were followed up for 6 months during which serum samples were collected at 15 day, 1 month, 3 month and 6-month intervals.

2.2. Sample Processing

Blood was collected in plain collection vials and sent to laboratory for investigation within 1-2 hours. Serum was separated from the blood using standard centrifugation at 5000 rpm for 15 minutes. Four aliquots were prepared for storage at -70°C until further testing was carried out.

2.3. Diagnostic Assays

CHIKV infection was diagnosed by IgM capture ELISA assay using serum samples from all suspected CHIK patients. Serum sample from suspected CHIK patients in 0-10 days duration of illness were also tested by Reverse transcriptase PCR (RT-PCR) targeting E1 gene.

2.3.1. CHIKV Specific IgM Capture ELISA

All Serum samples were tested using CHIKV specific IgM capture ELISA kit supplied by National Institute of Virology (NIV), Pune, India. Performance of ELISA and calculation of results were done by following manufacturer instructions.
Table 1. Primers used for RT-PCR amplification of E1

| Primer Name                        | Sequence of primer                  | Length of amplicon |
|-----------------------------------|-------------------------------------|--------------------|
| RT-PCR                            | [65]                                |                    |
| CHIK/E1-S                         | TACCCATTCAATGTGGGGC                 | 294 bp             |
| CHIK/E1-C                         | GCCTTGATACACCCAGATT                 |                    |
| PCR E1 gene primer (for Cloning)  | [66]                                |                    |
| 10445F                            | ACCATGCGGTACAGTAA                   | 804 bp             |
| 11296R                            | ACACGCATAGCACCGATTAGAA              |                    |
| Real time PCR primer probe        | [67]                                |                    |
| CHIK E1 F                         | TCGACGCGCTTCTTTAA                   | 10,865-10,882      |
| CHIK E1 R                         | ATCGAATGCACCGCACT                   | 10,973-10,991      |
| CHIK E1 P                         | ACCAGCCGTACCCCATTCTCAGAC           | 10,902-10,926      |

2.3.2. RNA Extraction and PCR

RNA from serum samples was isolated using Qiagen Viral RNA extraction kit as per manufacturer’s instruction. cDNA was prepared by using avian myeloblastosis virus reverse transcriptase (Promega Inc.). Partial E1 gene of CHIKV was amplified using published primers, Tag DNA Polymerase (Banglore Biogene India) with amplicon size of 294bp ([65]; Table 1). Amplification was visualized at 2% agarose gel using ethidium bromide under Gel Doc™ XR+ System (Biorad Inc.). Standard Ross strain was used as positive control in reactions. The standard strain of Chikungunya Virus (CHIKV) strain S27-African (Ross Strain) prototype was kindly provided by national Institute of Virology (NIV), Pune, India.

2.3.3. Quantitative real-time PCR (qRT-PCR)

2.3.3.1. Cloning of E1 Gene

E1 gene from RNA isolated from C6/36 cell line cultured standard Chikungunya African strain (S-27) was amplified using primers and Pfx polymerase enzyme (Invitrogen Life Technologies, Carlsbad CA, USA) ([68]; Table 1) that encompassed the real-time primer probe binding regions (Figure 2). RNA was extracted from standard (African strain) of Chikungunya virus and cDNA was prepared with random primers and Avian myeloblast virus Reverse transcriptase.

2.3.3.2. Purification of the PCR Product

The PCR product was resolved on a 1.5% agarose gel containing 0.5 µg/ml of ethidium bromide (EtBr), and the expected sized band was excised from the gel and purified using Gel extraction kit (QIAGEN GmbH, Germany), as per the manufacturer’s instruction.

2.3.3.3. A-tailing of the Gel Purified DNA and TA-cloning

The gel purified PCR product was A-tailed for TA-cloning using Taq DNA polymerase (Invitrogen Inc., USA). Ligation reaction was set up using the pGEM®-T Easy vector kit (Promega Corp., Madison, WI, USA).

2.3.3.4. Competent Cell Preparation and Transformation in E.coli

E. coli DH5α competent cells were prepared by CaCl₂ and transformation was done by heat shock method as described earlier [69]. Transformed cells were selected using Blue-white screening method. The white colonies were screened for the presence of insert by colony PCR using M13 universal primer followed by DNA sequencing.

2.3.3.5. Isolation of the Recombinant Plasmid

Positive colony was inoculated in 10 ml of Luria-Bertani broth with 100 µg/ml of ampicillin and grown overnight at 37°C. Plasmid DNA was isolated using the QIAprep Spin Miniprep Kit (Qiagen Inc., Gmbh, Germany) following the manufacturer’s instructions. The recombinant plasmids were sequenced using M13F and M13R universal primers commercially.

2.3.3.6. RNA Standards for Real Time PCR

*In Vitro* Transcription, Purification and transcription: Riboprobe system (Promega Corporation, USA) was used for in vitro transcription. The in vitro transcription reaction purification and estimation of RNA transcript was done in accordance with manufacturer’s instructions.

2.3.3.7. Real Time RT-PCR

The amplification target was 127 bp of E1 gene, which codes for the structural envelope protein E1 using published Primers and probe based on Taqman chemistry (Carolyn J. Edwards et al. 2007), (Table 1; Figure 2). The 18s rRNA internal control kit the “Ribosomal RNA control reagents” (Cat. No. 4308329) was obtained from Applied Biosystem Inc (Foster City CA, USA) and used as an endogenous/internal control for the Real Time PCR assay.

The real-time RT-PCR was carried out using the 7500 real-time PCR system (ABI, USA). A 20 µl reaction volume was used with the Superscript III Platinum one-step qRT-PCR system (Invitrogen).

The instrument by default is set to neglect any fluorescence value above baseline to be omitted between 3-15 cycles of real time RT-PCR. The ΔRn value can be translated into a quantitative result by constructing a standard curve.

Serial RNA dilutions containing 10⁴ to 10⁸ copies/ml were used to generate standard curve in real-time PCR.

2.4. Data Analysis

Variables were analyzed using percentage, mean and median. Chi-square tests were used to determine statistically significant differences between groups and p-value of less than 0.05 was considered as significant.
2.5. Ethical Approval

Ethics approval was obtained for this study from Ethics Committee of All India Institute of Medical Sciences, New Delhi, India (Ref. No IESC/T-343/02.09.2011 & RT-10/29.06.2012) (6-8-12).

3. Results

3.1. Socio Demographic and Clinical Data

All the patients belonged to NCR region of Delhi, India including Noida, Greater Noida, Ghaziabad and Faridabad. 

Patients with acute illness (<5 days duration)

During June 2010-December 2011, serum sample was collected from total of 2112 suspected Chikungunya patients were enrolled with less than/equal to 15 days of onset of symptoms. All sera were tested using IgM capture-ELISA (MAC-ELISA) assay. Blood samples that were received in laboratory on ice, were also tested for Chikungunya virus in serum by RT-PCR and in some samples viral load was also determined by real-time PCR assay.

Patients enrolled (2112) includes 964 (45.6%) females with age range of 6 months to 85 years (mean 33.4 years; median = 33 years) and 1148 (54.4%) males with age range of 6 months to 85 years (mean 32.1 years; median = 30 years) (Table 2; Figure 3).

Table 2. Demographics of patients enrolled with suspected Chikungunya acute illness (<15 days duration)

| Acute phase patients (n=2112) |  |
|------------------------------|---|
| Female (n=964)               | Male (n=1148) |
| Age range                    |  |
| 6 mo - 85 years              | 6 mo - 85 years |
| Mean                         |  |
| 33.4 years                   | 32.1 years |
| Median                       |  |
| 33 years                     | 30 years |

Figure 3. Age group and gender of patients enrolled with acute illness (<15 days duration)
Three hundred and twenty five (325; 15%) patients were from age group of 6 months to 15 years, 720 (34%) patients belonged to age group of 16 years to 30 years, 625 (30%) patients were of age between 31 years to 45 years and 442 (21%) patients belonged to age group of 46 years to 85 years (Table 3).

### Table 3. Age and gender wise distribution of suspected Chikungunya patients with acute illness (≤15 days duration)

| Age group       | Total | Male | Female | ODD ratio |
|-----------------|-------|------|--------|-----------|
| 6 months-15 years | 325   | 205  | 120    | 1.7       |
| 16-30 years     | 720   | 411  | 309    | 1.3       |
| 31-45 years     | 625   | 283  | 342    | 0.8       |
| >45 years       | 442   | 249  | 193    | 1.3       |
| **Total**       | **2112** | **1148 (54.4%)** | **964 (45.6%)** | **1.2**    |

Six hundred thirty three (633;30%) serum samples were collected from patients with 0 -5 days duration of illness, 1287 (61%) serum samples were collected from patients with 6-10 days duration of illness and 192 (9%) serum samples were collected from patients with 11-15 days duration of illness (Table 4).

### Table 4. Distribution by duration of illness of suspected Chikungunya patients enrolled with acute illness (<15 days duration)

| Duration of illness | Total | Male | Female | ODD Ratio |
|---------------------|-------|------|--------|-----------|
| 0-5 days            | 633   | 352  | 281    | 1.3       |
| 6-10 days           | 1287  | 703  | 584    | 1.2       |
| 11-15 days          | 192   | 93   | 99     | 0.9       |
| **Total**           | **2112** | **1148** | **964** | **1.2**    |

### Patients with Chronic illness

Serum samples were collected from 234 patients having 16 day to 12 months duration of polyarthralgia. All samples were tested by MAC-ELISA and RT- PCR was done on samples collected on ice. Total of two hundred and thirty four (234) patients were enrolled with chronic illness. These includes 138 (59%) females with age range of 3 years to 78 years (mean 38.1 years; median = 38.5 years) and 96 (41%) males with age range of 2 years to 80 years (mean 38 years; median = 38 years) (Table 5; Figure 4).

### Table 5. Demographics of patients enrolled with persisting polyarthralgia (Chronic illness; >15 days duration)

| Chronic patients (n=234) | Female (n=138) | Male (n=96) |
|--------------------------|---------------|-------------|
| Age range                |               |             |
| 3 -15 years              | 14            | 6           | 0.75       |
| 16-30 years              | 60            | 35          | 25         | 1.4        |
| 31-45 years              | 94            | 62          | 32         | 1.9        |
| >45 years                | 66            | 35          | 31         | 1.1        |
| **Total**                | **234**       | **138 (59%)** | **96 (41%)** | **1.4**    |

Fourteen (14; 6%) patients belonged to age group of 2 years - 15 years, 60 (26%) patients belonged to age group of 16 years - 30 years, 94 (40%) patients were of age between 31 years - 45 years and 66 (28%) patients belonged to age group of 46 years - 80 years (Table 6 and Table 6).

### Table 6. Age and gender wise distribution of patients with persisting polyarthralgia (Chronic illness; >15 days duration)

| Age group       | Total | Male | Female | ODD ratio |
|-----------------|-------|------|--------|-----------|
| 3-15 years      | 14    | 6    | 8      | 0.75      |
| 16-30 years     | 60    | 35   | 25     | 1.4       |
| 31-45 years     | 94    | 62   | 32     | 1.9       |
| >45 years       | 66    | 35   | 31     | 1.1       |
| **Total**       | **234** | **138** | **96** | **1.4**    |

One hundred thirty four (134) serum samples were collected from patients with 16 days - 1 month duration of illness, 73 serum samples were collected from patients with 1 month - 3 months duration of illness, 14 serum samples were collected from patients with 3 months - 6 months duration of illness and 13 serum samples were collected from patients with 1 year duration of illness (Table 7).

### Table 7. Distribution by duration of illness of patients enrolled with persisting polyarthralgia (Chronic phase; >15 days duration)

| Duration of illness | Total | Male | Female | ODD Ratio |
|---------------------|-------|------|--------|-----------|
| 16-1mo              | 134   | 58   | 76     | 0.8       |
| 1 mo -3 mo          | 73    | 29   | 44     | 0.7       |
| 3 mo - 6 mo         | 14    | 5    | 9      | 0.6       |
| 6 mo -1 yr          | 13    | 4    | 9      | 0.4       |
| **Total**           | **234** | **96** | **138** | **0.7**    |

![Figure 4. Age group and gender of patients enrolled with chronic illness (>15 days duration) (alt text)]
Follow-up patients

Seventy five (75) patients were followed up for 6 months during which blood samples were collected at 15 day, 1 month, 3 month and 6-month time intervals. All follow-up samples were screened for persistence of CHIKV specific IgM by MAC-ELISA and Chikungunya Virus in serum by reverse transcriptase PCR.

3.2. MAC ELISA

3.2.1. Patients with Acute Illness (<5 Days Duration)

Results of MAC ELISA in suspected Chikungunya patients with acute illness (<5 days duration)

All 2112 suspected serum samples from Chikungunya cases were tested for presence of CHIKV specific IgM in serum using MAC ELISA assay. Of these, 746 (35%) were found to be positive by ELISA. This included 383 (51.3%) females and 363 (48.7%) males. Most affected patients belonged to age group >30-45 yrs. and above in both genders (Table 8).

Total patients enrolled (2112) included 964 (45.6%) females of which 383 (40%) tested positive by ELISA and 1148 (54.4%) males of which 363 (32%) tested positive by ELISA (Table 8).

Of the 633 Samples collected from 0-5 days duration of illness, 177 (28%) tested positive by ELISA. Of the 1287 Samples collected from 6-10 days duration of illness, 468 (36%) tested positive by ELISA and out of 192 Samples collected from 11-15 days duration of illness, 101 (53%) were positive. (Table 9; Figure 5).

Table 8. Age group and gender wise distribution of suspected and MAC-ELISA positive Chikungunya patients with acute illness (<15 days duration)

| Age group     | Total  | Female | Male |
|---------------|--------|--------|------|
| 0-15 years    | 64/325 (20%) | 16/120 (13%) | 48/205 (23%) |
| 16-30 years   | 169/720 (23%) | 97/309 (31%) | 72/411 (18%) |
| 31-45 years   | 295/625 (47%) | 168/342 (49%) | 127/283 (45%) |
| >45 years     | 218/442 (49%) | 102/193 (53%) | 116/249 (47%) |
| Total         | 746/2112 (35%) | 383/964 (40%) | 363/1148 (32%) |

Table 9. CHIKV IgM positivity by duration of illness in Chikungunya patients with acute illness (<15 days duration)

| Duration of illness | Total samples collected | MAC-ELISA positive | Percentage Positivity |
|---------------------|-------------------------|--------------------|-----------------------|
| 0-5 days            | 633                     | 177                | 28%                   |
| 6-10 days           | 1287                    | 468                | 36%                   |
| 11-15 days          | 192                     | 101                | 53% *                 |
| Total               | 2112                    | 746                | 35%                   |

*p<0.001.

Figure 5. anti-CHIKV IgM positivity by duration of illness in patients with acute illness (<15 days duration)
Clinical features of suspected and confirmed (by anti-CHIKV IgM ELISA) patients of Chikungunya with acute illness (<5 days duration)

All patients (2112) enrolled in study had history of fever, 908 (42.9%) patients had polyarthralgia and 76 (3.6%) had rashes on whole body or parts like face, trunk, limbs and extensors. All Patients enrolled were having 1-15 days of illness duration with mean of 7 days (median = 7 days).

All 746 patients detected positive for CHIKV specific IgM had history of fever while 559 (75%) also had polyarthralgia and 29 (3.9%) gave history of rashes on different parts of body (Table 10).

Of the 363 ELISA positive male patients 100 % complained of fever, 265 (73%) had polyarthralgia and 16 (4%) gave history of rash on body parts. Of the 383 female ELISA positive all (100%) had fever, 294 (77%) had polyarthralgia and 13 (3%) had rashes on various body parts (Table 10).

Comparison of clinical features between anti-CHIKV IgM positive and anti-CHIKV IgM negative revealed that polyarthralgia had a high odds ratio (8.7) in IgM positive patients (Table 10).

Month wise distribution of acute Chikungunya cases (June 2010-Dec 2011)

Month wise distribution of total number of suspected acute Chikungunya patients enrolled and number positive by CHIKV specific IgM capture ELISA during the study period (June 2010- December 2011) is shown in Figure 6 and Table 11.

Maximum number of suspected cases (1679) were seen from August 2010 to November 2010. However % positivity remained high during most of the study period with maximum % positivity (59%-71%) from October 2010-January 2011.

Table 10. Comparison of clinical features among CHIKV IgM positive and CHIKV IgM negative patients of Chikungunya in acute phase (<15 days duration)

| Clinical feature of confirmed (CHIKV specific IgM positive) patients and CHIKV specific IgM negative patients | ODD ratio |
|---|---|
| Male (n=363) | Female (n=383) | Total 746 | Male (n=785) | Female (n=581) | Total 1366 | - |
| Features | | | | | | |
| Fever | 363 (100%) | 383 (100%) | 746 | 785 (100%) | 581 (100%) | 1366 | - |
| Polyarthralgia | 265 (73%) | 294 (77%) | 559/746 (75%) | 173 (22%) | 177(30%) | 350/1366 (25.6) | 8.6773* |
| Rashes | 16 (4%) | 13 (3%) | 29 (3.9%) | 31 (4%) | 16(3%) | 47/1366 (3.4%) | 1.1351 |

*p<0.001.

Table 11. Monthly distribution of suspected and confirmed by ELISA Chikungunya cases from suspected Chikungunya patients during the study period

| Month of sample collection | No of suspected cases enrolled | No of positive by anti-CHIKV IgM ELISA | Percentage positivity |
|---|---|---|---|
| Jun-10 | 21 | 1 | 5% |
| Jul-10 | 57 | 2 | 4% |
| Aug-10 | 492 | 40 | 8% |
| Sep-10 | 305 | 50 | 16% |
| Oct-10 | 459 | 271 | 59% |
| Nov-10 | 323 | 228 | 71% |
| Dec-10 | 36 | 22 | 61% |
| Jan-11 | 23 | 14 | 61% |
| Feb-11 | 10 | 2 | 20% |
| Mar-11 | 9 | 1 | 11% |
| Apr-11 | 11 | 4 | 36% |
| May-11 | 11 | 2 | 18% |
| Jun-11 | 11 | 4 | 36% |
| Jul-11 | 25 | 5 | 20% |
| Aug-11 | 21 | 6 | 29% |
| Sep-11 | 61 | 18 | 30% |
| Oct-11 | 121 | 28 | 23% |
| Nov-11 | 95 | 40 | 42% |
| Dec-11 | 21 | 8 | 38% |
| Total | 2112 | 746 | 35% |
3.3. Patients with Chronic Phase of Illness

Results of MAC-ELISA in samples collected from patients with chronic illness

All patients (234) enrolled had past history of fever and persisting polyarthralgia, eight patients also had history of rash on body parts.

All 234 suspected cases were tested for presence of CHIKV specific IgM in serum using MAC-ELISA assay. Of these, 156 (67%) were found to be positive by MAC-ELISA. This includes 92 (58.9%) females and 64 (41.1%) males. Most affected patients belonged to age group >30-45 yrs. and above in both genders (Table 12).

Of the 134 Samples collected from 16 days-1 month duration of illness, 84 (63%) tested positive by ELISA. Of the 73 Samples collected from more than 1 month-3 months duration of illness, 58 (79%) were positive, while out the 14 Samples collected from more than 3 months-6 months duration of illness, 8 were positive and Of the 13 Samples collected from more than 6 months - 1 year duration of illness 6 (46%) tested positive. (Table 13; Figure 7).

Table 12. Age group and gender wise distribution of patients with chronic polyarthralgia and MAC-ELISA positive Chikungunya patients. (Chronic illness; >15 days duration)

| Age group      | Total No. Positive/total No. tested (%) | Male No. Positive/total No. tested (%) | Female No. Positive/total No. tested (%) |
|----------------|----------------------------------------|----------------------------------------|----------------------------------------|
| 3-15 years     | 4/14 (29%)                             | 3/8 (38%)                              | 1/6 (17%)                              |
| 16-30 years    | 34/60 (57%)                            | 13/25 (52%)                            | 21/35 (60%)                            |
| 31-45 years    | 67/94(71%)                             | 26/32 (81%)                            | 41/62 (66%)                            |
| >45 years      | 51/66 (77%)                            | 22/31 (71%)                            | 29/35 (83%)                            |
| Total          | 156/234 (67%)                          | 64/96 (67%)                            | 92/138 (67%)                           |

Table 13. anti-CHIKV IgM positivity by duration of illness in Chikungunya patients with chronic illness (>15 days duration)

| Duration of illness | Total samples collected | MAC-ELISA positive | Percentage Positivity |
|---------------------|-------------------------|--------------------|-----------------------|
| 16-1mo              | 134                     | 84                 | 63%                   |
| 1mo -3 mo           | 73                      | 58                 | 79%                   |
| 3mo -6 mo           | 14                      | 8                  | 57%                   |
| 6 mo -1 yr          | 13                      | 6                  | 46%                   |
| Total               | 234                     | 156                | 67%                   |
Clinical features of suspected and confirmed (by anti-CHIKV IgM ELISA) patients with persisting polyarthralgia (chronic illness)

All patients (234) enrolled had past history of fever and persisting polyarthralgia, eight patients also had history of rash on body parts.

All 156 patients detected positive for CHIKV specific IgM had past history of fever and persisting polyarthralgia, while 5 (3%) reported history of rashes on their body.

Statistical analysis
We performed paired two-tail Pearson Chi2 t-test to detect any significant correlation. We analyzed all pairs of results during acute and chronic illness. We found significant correlation among acute phase results including, ELISA (p<0.001) and PCR positivity (p<0.01) in females, ELISA positivity in patients with 11-15 days duration of illness (p<0.001), ELISA positivity in patients with polyarthralgia (p<0.001) and PCR positivity in ELISA positive samples (p<0.001).

3.3. RT - PCR for E1 Gene in Chikungunya Patients

3.3.1. Samples from Acute Illness
We tested 290 serum samples that were received on ice for CHIKV RNA by RT-PCR. One hundred and thirty one samples (131; 45%) tested positive by RT-PCR. (Gel image of RT-PCR results is given in Figure 8).

Of the 144 Samples collected from 1-5 days duration of illness, 51 (35%)% were positive by RT-PCR, while from the 146 Samples collected from 6-10 days duration of illness, 62 (42.5%) tested positive by RT-PCR and out of 30 Samples collected from 11-15 days duration of illness, 18 (60%) were positive (Table 14).
Table 14. RT-PCR and IgM positivity among acute phase (<15 days duration) samples by duration of illness

| Duration of illness | RT-PCR results | IgM positive | IgM negative | Total |
|---------------------|----------------|--------------|--------------|-------|
| 1-5 day             | PCR positive  | 20 (17%)     | 31 (27%)     | 51    |
|                     | PCR Negative  | 18 (16%)     | 45 (40%)     | 63    |
| Total               |                | **38**       | **76**       | **114**|
| 6-10 day            | PCR positive  | 44 (30%)     | 18 (12%)     | 62    |
|                     | PCR Negative  | 24 (16%)     | 60 (41%)     | 84    |
| Total               |                | **68**       | **78**       | **146**|
| 11-15 day           | PCR positive  | 11 (37%)     | 7 (23%)      | 18    |
|                     | PCR Negative  | 5 (17%)      | 7 (23%)      | 12    |
| Total               |                | **16**       | **14**       | **30**|

Total PCR positive = 131 Total IgM positive=122 Both (Total) IgM and RT-PCR positive =75 * Total = 290

*p<0.05.

Table 15. RT-PCR and IgM positivity among chronic phase (>15 days duration) samples by duration of illness

| Duration of illness | RT-PCR results | IgM positive | IgM negative | Total |
|---------------------|----------------|--------------|--------------|-------|
| 16day-1mo           | PCR positive  | 11 (40%)     | 4 (16%)      | 15    |
|                     | PCR Negative  | 6 (22%)      | 6 (22%)      | 12    |
| Total               |                | **17**       | **10**       | **27**|
| 1-mo-3mo            | PCR positive  | 14 (50)      | 4 (15%)      | 18    |
|                     | PCR Negative  | 8 (28)       | 2 (7%)       | 10    |
| Total               |                | **22**       | **6**        | **28**|
| 3mo-8 mo.           | PCR positive  | 2 (33%)      | 0            | 2     |
|                     | PCR Negative  | 2(33%)       | 2(33%)       | 4     |
| Total               |                | **4**        | **2**        | **6** |

Total PCR positive = 35 # Total IgM positive=43 # Both (Total) IgM and RT-PCR positive =27 # Total = 61

#p>0.05.

Of the 114 samples collected with 0-5 days duration of illness, 20 samples tested positive by both RT-PCR and ELISA, 31 by RT-PCR only, 18 by ELISA only and 45 tested negative by both assays.

Of the 146 samples collected with 6-10 days duration of illness, 44 samples tested positive by both RT-PCR and ELISA, 18 by RT-PCR only, 24 by ELISA only and 60 tested negative by both assays.

Of 30 samples collected with 11-15 days duration of illness, 11 samples tested positive by both RT-PCR and ELISA, 7 by RT-PCR only, 5 by ELISA only and 7 tested negative by both assays (Table 15).

**Samples from Chronic illness**

Total of sixty one (61) serum samples were tested for CHIKV RNA by RT-PCR and 35 (57%) tested positive by RT-PCR. All patients (61) had previous history of fever, and polyarthralgia, three patients also had history of rashes on body parts.

These samples included, 27 collected from patients with 16 days to 1 month duration of illness, of which 15 tested positive by RT-PCR, 28 samples were collected from patients with more than one month to 3 months duration of illness and 18 of these were found positive by RT-PCR. From the samples (6) collected from patients with more than three months to 8 months duration of illness, two (2) tested positive by RT-PCR (Table 15).

Of the total thirty five (35) samples positive by RT-PCR, 27 were also positive by MAC-ELISA, and eight were negative by MAC-ELISA.

### 3.4. Follow up Patients

During this study we enrolled total of 118 confirmed patients who were followed up for 6 months to 1 year. One hundred eighteen (118) serum samples were collected at 15 days, 110 serum samples collected at 1 month, 118 serum sample collected at 3 months, 75 samples collected at 6 months and 12 samples were collected at 1 year duration of illness from these patients. (Table 16)

One hundred and eighteen (118) patients include 62 (52.5%) males and 56 (47.5%) females. Patients belonged to age group of 11 yrs. to 73 yrs. (mean 39.6 years; Median 40 years).

**MAC-ELISA and RT-PCR testing on follow-up patients samples**

Follow-up samples from 118 confirmed Chikungunya patients with 13-17 days (approx.15 days) duration of illness were collected, all 118 patients had polyarthralgia. Of these 118 serum samples all were positive by MAC-ELISA but only 34 (28.8%) were positive by RT-PCR (Table 16).
During second follow up at 25-33 days (approx. 1 month) of the initial 118 patients, 110 patients were available for sample collection. Of these 110 patients, 108 (98.2%) had polyarthralgia. Of these 110 serum samples 108 (98.2%) were positive by MAC-ELISA and only eight (8;7.3%) were positive by RT-PCR.

At third follow up at 82-107 days (approx. 3 months) all enrolled 118 patients were available for third sample collection. Of these 118 patients 113 (95.8%) had persisting polyarthralgia. Of these 118 serum samples 113 (95.8%) were positive by MAC-ELISA but only eight (8; 6.8%) were positive by RT-PCR.

At fourth follow-up period i.e. 168-198 days (approx. 6 months) of the 118 patients enrolled, 75 patients were available for sample collection. Of these 75 patients, 73 (97.3%) had polyarthralgia. Of these 75 Samples 73 (97.3%) were positive by MAC-ELISA but only three (3; 4%) were positive by RT-PCR.

At approx. 1-year time interval 12 of the 118 enrolled patients were available for for sample collection. All 12 patients had persisting polyarthralgia and sera from all 12 (100%) patients were positive by MAC-ELISA and none was positive by RT-PCR. (Table 16).

### 3.5. Real-time PCR

Of the 351 serum samples from suspected cases of acute Chikungunya, which were tested by RT-PCR, 222 samples were non-randomly selected for real-time PCR.

| Follow-up Time interval | Total patients enrolled | CHIKV IgM | RT-PCR | Both RT-PCR and CHIKV IgM |
|-------------------------|-------------------------|-----------|--------|--------------------------|
| 13-17 days              | 118                     | 118       | 34     | 34                       |
| 1 month (25-33 days)    | 110                     | 107       | 8      | 8                        |
| 3 months (82-107 days)  | 118                     | 113       | 8      | 8                        |
| 6 months (168-198 days) | 75                      | 73        | 3      | 3                        |
| 1 year (+20 days)       | 12                      | 12        | 0      | 0                        |

E1 gene template for quantification was prepared using pGEMT-easy vector cloning system (Figure 9 and Figure 10).

![Figure 9. Gel image of plasmid pGEMT-easy vector isolation](image1)

![Figure 10. Amplification plot showing ten fold serial dilutions of CHIKV in-vitro transcribed RNA (10⁻⁵- 10⁰) detected by Real Time PCR. PCR cycles (X axis) were plotted against fluorescence intensity (Y axis). The threshold cycle (Ct) is inversely proportional to starting amount of target material. Detection limit of Real Time RT-PCR for CHIKV: 10⁰copies/ml. B). Standard curve of showing ten fold serial dilutions of CHIKV in-vitro transcribed RNA detected by Real Time RT-PCR.](image2)
Figure 11. Amplification plot showing results of E1 gene specific Taqman Real-time reaction done of serum samples of suspected Chikungunya patient. PCR cycles (X axis) were plotted against fluorescence intensity (Y axis).

### Table 17. CHIKV viral load by duration of illness

| Duration of illness | 1-5 days   | 6-10 days  | 11-15 days | 15-30 days |
|---------------------|------------|------------|------------|------------|
| Mean viral load (copies/ml) | 2.3x10^6  | 2.6x10^4  | 8.0x10^3  | 4.7x10^3  |
| Standard error (copies/ml)     | ±2.2x10^6 | ±1.6x10^4 | ±3.1x10^3 | ±3.2x10^3 |

Of the 222 samples 115 (52%) were positive by real-time PCR for CHIKV RNA. These include 29 (25%) samples collected from patients with 1-5 days of illness duration, 39 (34%) samples collected from 6-10 days of illness duration, 20 (17%) samples from 11-15 days of illness, 15 (13%) samples collected from patients with 16 days-one month of illness duration, and 12 (10%) samples collected from more than one month to 3 months of illness duration.

Of the 115 real-time PCR positive samples 83 (72%) were also positive by RT-PCR (Figure 11).

Viral load was determined in 87 serum samples collected from patients with 1-30 days of illness duration. The mean viral load in samples with <5 days of disease duration was 2.3x10^6 (SE=±2296738) copies/ml, in samples from 6-10 day duration patients viral load was ≥2.6 X10^4 (SE=±16854) copies/ml, viral load in samples from 11-15 days duration was 8.0 x10^3 (SE=±3193) copies/ml and mean of 4.7 X10^3 (SE=±3251) copies/ml from samples of patients with 15-30 day duration. (Table 17)

### 4. Discussion

#### 4.1. Study

This is a prospective study carried out from June 2010 to December 2011 for a period of one and half year, where all patients referred to virology laboratory of All India institute of medical Sciences Delhi with suspected Chikungunya were enrolled. In addition, chronic Chikungunya cases with persisting polyarthralgia were also studied for the persistence of anti-CHIKV-IgM antibodies and CHIKV RNA. To further study the persistence of CHIKV and IgM antibodies in chronic cases, few patients with persisting polyarthralgia were followed up for a period of 1 year.

During the study period (June 2010-December 2011) only 230 clinically suspected cases of Chikungunya were reported by NVBDCP. However this is a gross underestimate because no systematic surveillance system for Chikungunya virus exists. From June 2010 to December 2011, 2112 suspected Chikungunya patients with acute illness were enrolled in the present study and of these 746(35%) were found to be positive for anti CHIKV IgM antibodies. In addition 290 samples which were received on ice, CHIKV RNA was also determined by RT-PCR and of these 131(45%) were found to be positive for CHIKV RNA. A total of 802 patients (38%) were confirmed to have Chikungunya infection during this period. Even the number reported in the present study is an underestimate of the total number of Chikungunya cases in Delhi NCR as this study was only carried out in 1 referral hospital of the NCR.

The age group most affected with Chikungunya infection in this study was adults above 30 years of age, though the number of suspected cases was quite high even in young adults the percentage of confirmed Chikungunya infection was seen in > 30 years age group. Our findings
are similar to other studies showing that adults are more affected by Chikungunya [1,17,70,71,72,73].

Higher percentage of women (8% more) was found to have confirmed Chikungunya infection as compared to males in the present study. Similar findings have been reported in other studies from Malaysia, Reunion Island and India [17,31,74,75], which may be due to higher exposure of women to the vector. This study is first report from Delhi reporting high frequency Chikungunya among female patients.

Laboratory diagnosis for Chikungunya rests on testing serum or plasma to detect virus, viral nucleic acid, or virus-specific immunoglobulin (Ig) M and neutralizing antibodies. Viral culture may detect virus (by isolation in mosquito cells, mammalian cells or mosquitoes or mice) in the first 3 days of illness; during the first 8 days of illness, Chikungunya viral RNA can often be identified in serum (CDC). Chikungunya virus antibodies normally develop toward the end of the first week of illness (>4-days) but can persist for several months even up to 1 year. Thus although detection of anti CHIKV IgM antibodies in acute phase is used for diagnosis of Chikungunya it can be present in patients even a year after the onset of disease. To definitively rule out the diagnosis, convalescent-phase samples should be obtained from patients whose acute-phase samples test negative. In the present study, all 2112 sera from suspected patients were tested for Chikungunya specific IgM antibodies using mu capture ELISA, and samples received on ice were also tested by RT-PCR for CHIKV RNA. Anti CHIKV IgM antibodies were detected in 35% of all suspected cases and CHIKV RNA was present in 45% of 290 samples tested. Anti-CHIKV positivity in suspected Chikungunya cases of 13%-80% was reported from India [70,71,73,76] and anti-CHIKV IgM positivity of 22%-80% was reported in patients from Thailand [31], and in travelers returning to France [77] and Germany [78].

CHIKV RNA is usually detected during first 8 days of illness with maximum positivity (up to 100%) in first 4-5 days of illness [31], however in the present study during first 5 days of illness 44.7% of suspected patients were positive for CHIKV RNA and in the same set of patients 33% also had CHIKV specific IgM antibodies. In patients with 6-10 days of duration of illness CHIKV RNA was seen in 42.5% of patients and CHIKV IgM antibodies were seen in 46.6% of patients. Interestingly CHIKV RNA was also detected in 60% of patients with 11-15 days duration of illness. These findings are somewhat different than other studies which have shown CHIKV RT-PCR positivity of 100% and anti-CHIKV IgM antibodies in only 10% of patients during first 4 days of illness [31]. This may be due to better patient selection in their study. Further we had to depend on patient’s history for duration of illness, which may not always be correct.

In the present study in patients with 0-5 days duration of illness CHIKV IgM antibodies were positive in 28%, in patients with 6-10 days duration of illness in 36% and in patients with 11-15 days duration of illness in 53%. Thus there was an increase in IgM positivity with increasing duration of illness. Similar increasing trends of Anti-CHIKV IgM positivity were shown in Chikungunya patients in a study from India where IgM positivity increased from 10% to 95% from day 1 to 7 post onset of illness. Similarly in a study from Thailand IgM positivity in confirmed patients increased from day 1 and became 100% by day 7-8 and then remained at 100% till Day >17 [31].

In acute phase common clinical features seen in Chikungunya patients are fever, polyarthralgia, and rashes these can also differentiate Chikungunya from other similar infections [1,39,79]. Other atypical symptoms including neurological manifestation were reported in Indian Patients [71,80]. Chikungunya associated deaths were also reported in Chikungunya confirmed patients in La reunion [17]. In the present study of 746 anti-CHIKV IgM positive patients all gave history of fever, 75% complained of polyarthralgia, while only 3.9% complained of rashes on body parts. No case of encephalitis or mortality was seen in this study. In other studies from India 95-100% of Chikungunya patients had fever, 62%-80% had joint pains and 10-36% had rashes [70,74,81,82].

In this study maximum number of Chikungunya cases were seen during September 2010 to November 2010 and then during September to November of 2011 that is during and post monsoon season in North India. Chikungunya is known to be transmitted by mosquito vector belonging to Aedes species with most common agents are Aedes aegypti and A. albopictus mosquitoes [83]. Although both Aedes aegypti and A. albopictus mosquitoes are prevalent in India, the former is the main vector of Chikungunya virus and is prevalent in tropical areas. Both mosquitoes require high humidity and high temperature for the breeding [68]. During our study period, in 2010 National Capital territory of India witnessed a heavy rainfall during monsoon season, which provided the ideal conditions for the breeding of mosquitoes and for transmission of Chikungunya Virus that results in large number of Chikungunya infections. It also explains that although Delhi was considered to be a low prevalence zone for Chikungunya, but during the study period Delhi emerged as a major center of Chikungunya infection.

To further assess the presence of CHIKV RNA and IgM antibodies over time, 118 Chikungunya confirmed patients with persistent polyarthralgia were followed up with 75 patients being followed up till 6 months and 12 till 1 year. Of these 118 patients positive for anti-CHIKV IgM antibodies persistence of anti-CHIKV IgM was seen till 3 months in 95.7% of patients where as at 6 months follow up only 75 samples were available of which 73 were positive for anti-CHIKV IgM antibodies. CHIKV RNA was present in 34 of these patients at 2 weeks and could be detected in 3 patients even at 6 months. At 1 year only 12 samples were available all were anti-CHIKV IgM positive and none were positive for CHIKV RNA. This is a the only study as far as we know where anti-CHIKV IgM antibodies, RNA and information on persistence of polyarthralgia was collected in follow up samples. In a previous study from India anti-CHIKV IgM antibodies have been shown to persist for 2-4 months in 52% of patients with persistent polyarthralgia and in only 1.2% patients at 6-8 months. In both recovered and chronic disease group anti-CHIKV IgM antibodies were shown to persist up to 12 months in a study from la reunion island [46]. However no studies are available on the persistence of CHIKV RNA in blood for a long time in chronic disease.
In experimental studies in mice persistence of CHIKV RNA in joint-associated tissues has been shown for at least 16 weeks. Inoculation of Rag1−/− mice, which lack T and B cells, resulted in higher viral levels in a variety of tissues, suggesting that adaptive immunity controls the tissue specificity and persistence of CHIKV infection. The presence of CHIKV RNA in tissues of wild-type and Rag1−/− mice was associated with histopathological evidence of synovitis, arthritis, and tendonitis. Further, these authors showed that CHIKV-induced persistent arthritis is not mediated primarily by adaptive immune responses but musculoskeletal tissue pathology is caused by persistent CHIKV infection and controlled by adaptive immune responses [84]. In experimental study using immunocompetent adult nonhuman primates, CHIKV persists was seen in lymphoid tissues, liver, joints, and muscles for up to 3 months and is able to replicate in spleen, liver, and muscle for extended periods. Furthermore, results of in situ hybridization assays suggested that the virus persists mainly in mononuclear cells and, to a lesser extent, in endothelial cells [85].

However, human studies where CHIKV RNA can be demonstrated in joint tissues in persistent polyarthritis are ethically difficult to carry out but even persistence of viral RNA in blood in this study points towards continued viral replication at low level in body may be joint tissues. Chikungunya virus confirmed by RT-PCR (10-40%) in serum samples from acute illness (<7 days) had been reported in studies from India, Thailand, La reunion, Italy, and Germany [31,43,45,70,78,82,86]. It has been reported that during first 4 days of illness CHIKV RNA can be detected in 80-100% of patients where as IgM antibody is detected in only 10% of patients [31]. In the present study during first 5 days of illness CHIKV RNA was detected in 44.7% of 114 patients and IgM antibodies in 28% of 633 patients Chikungunya viral RNA can often be identified in serum of first 4 days illness duration patients (CDC, USA). In the present study presence of CHIKV RNA in patients sera of acute and chronic illness (1 day-3 months) was detected by RT-PCR for E1 gene. Sixty eight percent (68%) of the RT-PCR positive serum samples were from patients with 1-10 days of illness duration, RT-PCR percentage positivity was seen to decrease with increased duration of illness.

**Persistent arthralgia**

There are very few studies on long term clinical outcome of CHIKV infection and earlier studies showed lower prevalence of persistent arthralgia. However studies carried out after the Indian Ocean epidemic showed a much higher rate of persistent arthralgia. Persisting polyarthritis in chronic phase of disease has been previously reported for 1 year to 3 years in different studies from South Africa, Singapore, France, Germany, La Reunion, Colombia, USA and India [15,45,48,74,87,88,89,90,91,92,93,94,95,96].

Persisting polyarthritis has been seen in Chikungunya patients in studies from India and La Reunion [45,97], however in some studies presence of viral markers including anti CHIKV IgM was reported but CHIKV RNA in chronic illness has not been studied. In the present study 234 patients with persisting polyarthritis during chronic illness, were tested for presence of viral markers i.e. anti CHIKV IgM antibodies and CHIKV RNA.

Persisting polyarthritis was complained by all patients during >16 days of illness. Thirty three (33%) patients complained of Polyarthralgia but were negative for anti-CHIKV IgM antibodies. Polyarthritis is a common feature of Chikungunya infection but it is also associated with other diseases. In a study from La Reunion, DC Andrade et al. 2010 reported persisting polyarthritis in 16% chronic Chikungunya patients with 1 month duration of illness, in 33% patients with 3 months duration, and in 53% with 10 months duration of illness. In previous studies persisting polyarthritis for 1 month - 30 months was reported among Chikungunya patients from Indian states including Kerala, Tamil Nadu, Karnataka, Assam, Maharashtra [73,97,98,99,100] and other countries including France south Africa, Singapore, France, Germany and La Reunion [15,48,92,93,94,95,96,101,102].

**4.2. Anti-CHIKV IgM**

Anti-CHIKV IgM antibodies was seen with 63%-79% positivity during 1 month to 3 months duration of illness and positivity was declined with increasing duration of illness with 57% by 6 months and 46% by 1 year. In previous reports presence of anti-CHIKV IgM for 1 month to 18 months in chronic illness patients was reported from India, Thailand, Germany, La Reunion and Singapore CHIKV specific IgM [15,31,45,48,70,94,98,99].

Similarly, CHIKV RNA was detected in 55-64% of samples with 1 month - 3 months illness duration; CHIKV RNA was also detected in two patients at 8 months duration. Hoarau et al. [45] also reported presence of CHIKV in synovial macrophage in chronic Chikungunya patients with 18 months of illness duration.

**4.3. Viral Load**

High Chikungunya viral load (10^8 copies/ml) was seen in patients with <7 days duration of illness in serum from acute phase Chikungunya patients from La Reunion Island [93,103]. In the present study Chikungunya viral loads were estimated in serum of Chikungunya patients with 1-30 days duration of illness. Maximum viral load (10^8 copies/ml) was seen in serum samples taken from <5 days of illness, following that viral load exponentially reduced with increasing duration of illness with minimum of 10^3 copies/ml in serum of patients with 15-30 days of illness. In previous studies from India, CHIKV Viral load of 10^5-10^6 copies/ml has been seen in Chikungunya patients with acute illness (<7 days) from Madhya Pradesh, Andhra Pradesh and Karnataka [81,104]. Similar reduction in CHIKV load with increasing duration of illness were previous reports from La Reunion, Italy, Germany and Singapore [78,86,92,93,103,105]. Furthermore, presence of Chikungunya virus for 30 days duration also confirm the idea of long term Chikungunya persistence by Laurent et al. [106] who previously reported 10^3 copies of CHIKV in 12 day illness duration samples. In experimental studies CHIKV persistence was seen for 15 days and 2 months post CHIKV inoculation in mouse model and nonhuman primate macaques, respectively [85,107].
5. Conclusion

Thus, this is the first comprehensive prospective study of Chikungunya infection in Delhi NCR region, which describes the epidemiology and prevalence of disease. This study suggests higher percentage of affected women as compared to male. This study also suggest the need of well-organized surveillance for Chikungunya infection to report accurate number of cases in NCR region.

Funding Agency

Study was carry out by the funds provided by Department of biotechnology MHRD, Government of India under Indo Australia collaborative project funding scheme.

References

[1] Robinson, Marion C. “An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952-1953.” Transactions of the Royal Society of Tropical Medicine and Hygiene. 49, no. 1 (1955): 28-32.

[2] Straus, James H., and Ellen G. Straus. “The alphaviruses: gene expression, replication, and evolution.” Microbiological reviews 58, no. 3 (1994): 491.

[3] Sinizu, K., B. Yamamoto, K. Hashimoto, and T. Ogata. “Structural proteins of Chikungunya virus.” Journal of virology. 51, no. 1 (1984): 254-258.

[4] Diao, Mawouth, Joselyn Thonnon, Mumouni Traore-Lamizana, and Didier Fontenille. “Vectors of Chikungunya virus in Senegal: current data and transmission cycles.” The American journal of tropical medicine and hygiene. 60, no. 2 (1999): 281-286.

[5] Kumar, N. Pradeep, Rajan Joseph, T. Kamaraj, and P. Jambulingam. “2026V mutation in virus during the 2007 chikungunya outbreak in Kerala, India.” Journal of General Virology. 89, no. 8 (2008): 1945-1948.

[6] McIntosh, B. H. E. Paterson, J. M. Donaldson, and J. De Sousa. “Chikungunya virus: viral susceptibility and transmission studies with some vertebrates and mosquitoes.” S Afr J Med Sci. 28 (1963): 45-52.

[7] Powell, Ann M., and Christopher H. Logue. “Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus.” Journal of General Virology. 88, no. 9 (2007): 2363-2377.

[8] Mackenzie, J. S., K. B. Chua, P. W. Daniels, B. T. Eaton, H. E. Field, R. A. Hall, K. Halpin et al. “Emerging viral diseases of Southeast Asia and the Western Pacific.” Emerging infectious diseases 7, no. 3 Suppl (2001): 497.

[9] Burt, Felicity J., Micheal S. Rolph, Nestor E. Rulli, Suresh Diallo, Mawlouth, Joselyn Thonnon, Mumouni Traore-Lamizana, and Didier Fontenille. “Virus expression, replication, and evolution.” Journal of virology. 70, no. 1 (1995): 28-32.

[10] Taubitz, Winfried, Jakob P. Cramer, Anette Kapau, Martin Pfeffer, Christian Drosten, Gerhard Dobler, Gerd D. Burchard, and Thomas Loscher. “Chikungunya fever in travelers: clinical presentation and course.” Clinical Infectious Diseases. 45, no. 1 (2007): e1-e4.

[11] Hochedez, P., P. Hausfater, S. Jauregubierry, F. Gay, A. Datry, M. Danis, F. Bricaire, and P. Bossi. “Cases of chikungunya fever imported from the islands of the South West Indian Ocean to Paris, France.” Euro surveillance: bulletin European sur les maladies transmissibles European communicable disease bulletin. 12, no. 1 (2007).

[12] Renault, Philippe, Jean-Louis Solet, Daouda Sisoko, Elsa Baileyde, Sophie Larrieu, Laurent Filleul, Christian Lassalle et al. “A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006.” The American journal of tropical medicine and hygiene. 77, no. 4 (2007): 727-731.

[13] Borgia, Gianandrea, Patrice Poubeau, Frederik Staikowsky, Manuela Lory, Nathalie Le Mouillé, Jérome Pueyo, Catherine Wengling, Alain Michaut, and Frédéric Paganin. “Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients.” Clinical infectious diseases. 44, no. 11 (2007): 1401-1407.

[14] Sanchez, C., Barboza, L.A., Burton, D. and Cintrón-Arias, A., 2018. Comparative analysis of dengue versus chikungunya outbreaks in Costa Rica. Ricerche di Matematica, 67(1), pp.163-174.

[15] Paul, B.J. and Sadanand, S., 2018. Chikungunya Infection: A Re-emerging Epidemic. Rheumatology and therapy, pp.1-10.

[16] Calba, C., Gueboin-Galla, M., Franke, F., Jeanin, C., Auzet-Caillaud, M., Grard, G., Pigaglio, L., Cadieux, B., de Lamballerie, X., Paty, M.C. and Leparc-Goffart, I., 2018. Investigation of an autochthonous chikungunya outbreak, July-September 2017. Revue d’Épidémiologie et de Santé Publique. 66, pp.S387-S388.

[17] Venturi, G., Di Luca, M., Fortuna, C., Renoli, M.E., Riccardo, F., Severini, F., Tona, L., Del Misso, M., Benedetti, E., Caporali, M.G. and Amendola, A., 2017. Detection of a chikungunya outbreak in central Italy, August to September 2017. Eurosurveillance, 22(39).

[18] Delisle, E., Rousseau, C., Brôche, B., Leparc-Goffart, I., L’ambert, G., Cochet, A., Prat, C., Foulon, V., Ferre, J.B., Guerin, O., and Flusin, O., 2015. Chikungunya outbreak in montpellier, France, September to October 2014. Eurosurveillance, 20(17), p.21108.

[19] Weaver, Scott C. “Arrival of Chikungunya Virus in the New World: Prospects for Spread and Impact on Public Health.” PLOS Neglected Tropical Diseases 8, no. 6 (2014): e2921.

[20] Leparc-Goffart, Isabelle, Antoine Nougarede, Sylvie Cassadou, Christine Prat, and Xavier de Lamballerie. “Chikungunya in the Americas.” Lancer 383, no. 9916 (2014): 514.

[21] Wangchuk, Sonam, Piyawan Chinnawirotpisan, Tsherji Dorji, Tashi Tobgay, Tandin Dorji, In-Kyu Yoon, and Stefan Fernandez. “Chikungunya fever outbreak, Bhutan, 2012.” Emerging infectious diseases 19, no. 10 (2013): 1681.

[22] Wu, De, Jie Wu, Qiaozi Zhang, Xiaoling Deng. “Chikungunya outbreak in Guangdong province, China, 2010.” Emerging infectious diseases 18, no. 3 (2012): 493.

[23] Duong, Vanan, Anne-Claire Andries, Chantal Ngan, Touch Sok, Beat Richner, Nima Asgari-Jirhandeh, Steve Bjorge et al. “Reemergence of Chikungunya virus in Cambodia.” Emerging infectious diseases 18, no. 12 (2012): 2066.

[24] Grandadam, Marc, Valérie Caro, Sébastien Thibierge, Yvan Souarès, Anna-Bella Failloux, Hugues J. Tolou et al. “Chikungunya virus, southeastern France.” Emerging infectious diseases 17, no. 5 (2011): 910.

[25] Gould, E. A., P. Gallian, X. De Lamballerie, and R. N. Charrel. “First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality!” Clinical microbiology and infection 16, no. 12 (2010): 1702-1704.

[26] Rianthavorn, Pompimol, Kesmanee Priananathavorn, Norra Wittitrattanakorn, Prinya Atrisai, Theamboonlers, and Yong Poonorawon. “An outbreak of chikungunya in southern Thailand from 2008 to 2009 caused by African strains with A226V mutation.” International Journal of Infectious Diseases 14 (2010): e161-e165.
[32] Paupy, Christophe, Benjamin Ollomo, Basile Kamgang, Sara Moutailler, Dominique Rousset, Maurice Demanou, Jean-Pierre Hervé, and Frédéric Simard. “Comparative role of Aedes albopictus and Aedes aegypti in the emergence of dengue and chikungunya in Central Africa.” Vector-Borne and Zoonotic Diseases 10, no. 3 (2010): 259-266.

[33] Leo, Yee S., Angela LP Chow, Li Kang Tan, David C. Lye, Li Lin, and Lee C. Ng. “Chikungunya outbreak, Singapore, 2008.” Emerging infectious diseases 15, no. 5 (2009): 736.

[34] Ng, Lisa FP, Angela Chow, Yong-Jiang Sun, Dyan JC Kwek, Poh-Lim Lim, Frederico Dimattata, Lee-Ching Ng et al. “IL-1β, IL-6, and RANTES as biomarkers of Chikungunya severity.” PLoS one 4, no. 1 (2009): e261.

[35] Leroy, Eric M., Deudoné Nkoghe, Benjamin Ollomo, Ghislaine Li-Pat-Yuen, Bérengère Giry, Philippe Renault, and Denis Malvy. “Concurrent chikungunya and dengue virus infections during simultaneous outbreaks, Gabon, 2007.” Emerging infectious diseases 15, no. 4 (2009): 591.

[36] Sam, I., Yoke Fun Chan, Shie Yien Chan, Shi Keng Loong, Hock Khim Chin, Poh Sim Hooi, Rajasekaram Ganeswrie, and Szazaly Abu Bakar. “Chikungunya virus of Asian and central/east African genotypes in Malaysia.” Journal of Clinical Virology 46, no. 2 (2009): 180-183.

[37] Schuffenecker, Isabelle, Isabelle Iteman, Alain Michault, Séverine Murri, Lionel Frangule, Marie-Christine Vaney, Rachel Lavener et al. “Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak.” PLoS medicine 3, no. 7 (2006): e263.

[38] Charrel, Remi N., Xavier de Lamballerie, and Didier Raoult. “Chikungunya outbreaks-the globalization of vectorborne diseases.” New England Journal of Medicine. 356, no. 8 (2007): 769.

[39] WHO http://www.who.int/csr/don/2006_10_17/en/

[40] Mavalankar, Dileep, Priya Shastri, and Parvathy Raman. “Chikungunya epidemic in India: a major public-health disaster.” The Lancet infectious diseases ? , no. 5 (2007): 306-307.

[41] AbuBakar, Szazaly, I-Ching Sam, Pooi-Fong Wong, NozAriyah MatRahim, Poh-Sim Hoot, and Nuruliza Roslan. “Reemergence of endemically chikungunya, Malaysia.” Emerging infectious diseases 13, no. 1 (2007): 147.

[42] Peyrefitte, Christine N., Maël Bessaud, Boris AM Pastorino, Patrick Gravier, Sébastien Plumet, Olivier L. Merle, Isabelle Moltini et al. “Circulation of Chikungunya virus in Gabon, 2006-2007.” Journal of medical virology 80, no. 3 (2008): 330-343.

[43] Rezza, G., L. Nicoletti, R. Angelini, R. Romi, A. C. Finarelli, M. Myers. “Chikungunya disease in infants and children in Italy: an outbreak in a temperate region.” The Lancet infectious diseases 7, no. 8 (2007): 942-948.

[44] Muzzo, Yasutaka, et al. “Clinical and radiological features of imported chikungunya fever in Japan: a study of six cases at the National Center for Global Health and Medicine.” Journal of Infection and Chemotherapy 17.3 (2011): 419-423.

[45] Hoarau, Jean-Jacques, Marie-Christine Jaffar Bandjee, Pascale Kukreti, Himani, Artee Chaudhary, R. S. Rautela, Ranjana Anand, Veena Mittal, Mala Chhibra, D. Bhattacharya, Shiv Lal, and Arvind Rai. “Emergence of an independent lineage of dengue virus type 1 (DENV-1) and its co-circulation with predominant DENV-3 during the 2006 dengue fever outbreak in Delhi.” International journal of infectious diseases 12, no. 5 (2008): 542-549.

[46] NVBDCP http://www.nvbdcp.gov.in/Chikun-main.html.

[47] Hasebe, F. M., C. Paquet, B. D. Pandey, E. G. M. Mathenge, K. Morita, V. Balasubramaniam, Z. Saat et al. “Combined detection and genotyping of Chikungunya virus by a specific reverse transcription-polymerase chain reaction.” Journal of medical virology 67, no. 3 (2002): 370-374.

[48] Santhosh, S. R., et al. “Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates.” Virus Research 135.1 (2008): 36-41.

[49] Edwards, Carolyn J., et al. “Molecular diagnosis and analysis of Chikungunya virus.” Journal of clinical virology 39.4 (2007): 271-275.

[50] Santhosh, S. R., P. K. Dash, M. M. Parida, M. Khan, M. Tiwari, and P. V. Lakshmana Rao. “Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates.” Virus research 135, no. 1 (2008): 36-41.

[51] Ray, Pratima, Vinod H. Ratagiri, Sushil K. Kabra, Rakesh Lodha, Sumit Sharma, B. S. Sharma, Mani Kalaiavani, and Naveet Wig. "Emerging infectious disease cohort study in India: 2007-2008." Infectious Diseases (An International Journal) 18.5 (2010): 30-33.
“Chikungunya infection in India: results of a prospective hospital-based multi-centric study.” PLoS one 7, no. 2 (2012): e30025.

Suryawanshi, R.N., M. A. Desai, S. V. Jugalakshmr, P. S. Sathe, S. D. Zawar, and M. P. Holay. “Clinical profile of chikungunya fever in patients in a tertiary care centre in Maharashtra, India.” (2009).

Kaur, Prabhdeep, Manickam Ponniah, Maneo V. Murhekar, Vidya Ramachandra, Ramakrishnan Ramachandran, Hari Kishan Raja, Vanamani Parom, Akhilesh C. Mishra, and Mohan D. Gupta. “Chikungunya outbreak, south India, 2006.” Emerging infections diseases 14, no. 10 (2008): 1623-1625.

Yergolkar, Prasanna N., Babasahab V. Tandale, Vidya A. Arankanle, Padmakar S. Sathe, Sudeep AB, Swati S. Gandhe, Mangesh D. Gokhle, George P. Jacob, Supriya L. Handeker, and Akhilesh C. Mishra. “Chikungunya outbreaks caused by African genotype, India.” Emerging infectious diseases 12, no. 10 (2006): 1580.

Chopra, Arvind, and Anuradha Venugopalan. “Persistent rheumatic musculoskeletal pain and disorders at one year post-chikungunya epidemic in south Maharashtra—a rural community based observational study with special focus on naïve persistent rheumatic musculoskeletal cases and selected cytokine expression.” Indian Journal of Rheumatology 6, no. 1 (2011): 5-11.

Selvanivayagam, T. S. “Chikungunya fever outbreak in Vellore, south India.” Indian Journal of community medicine 32, no. 4 (2007): 286.

Shrein, Jatin, Shamu Jain, Anil Sharma, Shashi Shekhar Staikowsky Staikowsky, Kalika Mathur, Vandita Rana, Raj K. Bhatnagar et al. “Genetic characterization of Chikungunya virus from New Delhi reveal emergence of a new molecular signature in Indian isolates.” Virol J 9 (2012): 100.

Win, M. K., et al. “Chikungunya fever in Singapore: acute clinical and laboratory features, and factors associated with persistent arthralgia.” Journal of Clinical Virology 49.2 (2010): 111-114.

Panning, Marcus, Klaus Grywna, Marjan Van Esbroeck, Petra Emmerich, and Christian Drosten. “Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006.” Emerging infections diseases 14, no. 3 (2008): 416.

C DC http://wwwnc.cdc.gov/eid/article/14/10/107-0569_artic le.

Leithwaite, Penny, Ravi Vasanthapuranam, Jane C. Osborne, Ashia Begum, Jenna LM Plank, M. Veera Shankar, Roger Hewson et al. “Chikungunya virus and central nervous system infections in children, India.” Emerging infectious diseases 15, no. 2 (2009): 329.

Son, Manisha, Anil Kumar Singh, Shashi Sharma, Ankita Agarwal, Natarajan Gopalan, P. V. Rao, Mannomohan Parida, and Paban Kumar Das. “Molecular and Virological Investigation of a Focal Chikungunya Outbreak in Northern India.” The Scientific World Journal 2013 (2013).

Singh, Priyanka, Veena Mittal, Mosahid A. Rizvi, Dipesh Bhattacharya, Mala Chhabra, Devendra S. Rawat, Rattan L. Ichhpujani, Lakhvir S. Chauhan, and Arvind Rao. “Chikungunya virus and central nervous system infection in children, India.” Emerging infectious diseases 15, no. 2 (2009): 329.

Lambrechts, Loui, Thomas W. Scott, and Duane J. Gubler. “Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission.” PLoS neglected tropical diseases 4, no. 5 (2010): e646.

Hawman, David W., Kristina A. Stoermer, Stephanie A. Ichhpujani, Lakhvir S. Chauhan, and Arvind Rai. “Northward movement of East Central South African genotype of Chikungunya virus causing an epidemic between 2006-2010 in India.” The Journal of Infection in Developing Countries 6, no. 07 (2012): 563-571.

Lambrechts, Louise, Thomas W. Scott, and Duane J. Gubler. “Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission.” PLoS neglected tropical diseases 4, no. 5 (2010): e646.

Hawman, David W., Kristina A. Stoermer, Stephanie A. Ichhpujani, Lakhvir S. Chauhan, and Arvind Rai. “Northward movement of East Central South African genotype of Chikungunya virus causing an epidemic between 2006-2010 in India.” The Journal of Infection in Developing Countries 6, no. 07 (2012): 563-571.

Lambrechts, Louise, Thomas W. Scott, and Duane J. Gubler. “Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission.” PLoS neglected tropical diseases 4, no. 5 (2010): e646.
[102] de Andrade, Daniel C., Sylvain Jean, Pierre Clavelou, Radhouane Dallel, and Didier Bouhassira. “Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness.” *BMC infectious diseases* 10, no. 1 (2010): 31.

[103] Parola, Philippe, Xavier De Lamballerie, Jacques Jourdan, Clarisse Rovery, Véronique Vaillant, Philippe Minodier, Philippe Brouqui, Antoine Flahault, Didier Raoult, and Rémi N. Charrel. “Novel chikungunya virus variant in travelers returning from Indian Ocean islands.” *Emerging infectious diseases* 12, no. 10 (2006): 1493.

[104] Parida, M. M., S. R. Santhosh, P. K. Dash, N. K. Tripathi, V. Lakshmi, N. Mamidi, A. Shrivastva et al. “Rapid and real-time detection of Chikungunya virus by reverse transcription loop-mediated isothermal amplification assay.” *Journal of clinical microbiology* 45, no. 2 (2007): 351-357.

[105] Carletti, Fabrizio, Licia Bordi, Roberta Chiappini, Giuseppe Ippolito, Maria R. Sciaronne, Maria R. Capobianchi, Antonino Di Caro, and Concetta Castilletti. “Rapid detection and quantification of Chikungunya virus by a one-step reverse transcription-polymerase chain reaction real-time assay.” *The American journal of tropical medicine and hygiene* 77, no. 3 (2007): 521-524.

[106] Laurent, Philippe, Karin Le Roux, Philippe Grivard, Gérard Bertil, Florence Naze, Miguel Picard, Frédéric Staikowsky, Georges Barau, Isabelle Schuffenecker, and Alain Michault. “Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus.” *Clinical chemistry.* 53, no. 8 (2007): 1408-1414.

[107] Dhanwani, Rekha, Mohsin Khan, Vinay Lomash, Putcha Venkata Lakshmana Rao, Hinh Ly, and Manmohan Parida. “Characterization of Chikungunya Virus Induced Host Response in a Mouse Model of Viral Myositis.” *PloS one.* 9, no. 3 (2014): e92813.

[108] Inamadar, Arun C., Aparna Palit, V. V. Sampagavi, S. Raghunath, and N. S. Deshmukh. “Cutaneous manifestations of chikungunya fever: observations made during a recent outbreak in south India.” *International journal of dermatology.* 47, no. 2 (2008): 154-159.

© The Author(s) 2020. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).